Disclosure of Directors and Senior Managers Relevant Intere

Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: AFT Pharmaceuticals Limited (AFT) Date this disclosure made: 17-Jun-20 Date of last disclosure: 13-Dec-18 Director or senior manager giving disclosure Full name(s): David Flacks Name of listed issuer: AFT Pharmaceuticals Limited (AFT) Name of related body corporate (if applicable): Not applicable Position held in listed issuer: Director Summary of acquisition or disposal of relevant interest (excluding specified derivatives) Class of affected quoted financial products: Fully-Paid Ordinary Shares in AFT Nature of the affected relevant interest(s): Joint registered holder and beneficial owner of ordinary shares For that relevant interest- Number held in class before acquisition or disposal: 145,431 Number held in class after acquisition or disposal: 165,431 Current registered holder(s): Unknown Registered holder(s) once transfers are registered: David Mark Flacks & Adina Rita Betty Halpern as trustees of Waitemata Family Trust Details of transactions giving rise to acquisition or disposal Total number of transactions to which notice relates: 1 Details of transactions requiring disclosure- Date of transaction: 15-Jun-20 Nature of transaction: On-market acquisition of ordinary shares Name of any other party or parties to the transaction (if known): Unknown The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: NZ$3.866475 per share / $77,329.50 Number of financial products to which the transaction related: 20,000 If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details-- Whether relevant interests were acquired or disposed of during a closed period: No Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: Not applicable Date of the prior written clearance (if any): Not applicable Summary of other relevant interests after acquisition or disposal: Class of quoted financial products: Not applicable Nature of relevant interest: Not applicable For that relevant interest,- Number held in class: Not applicable Current registered holder(s): Not applicable For a derivative relevant interest,- Type of derivative: Not applicable Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): Not applicable A statement as to whether the derivative is cash settled or physically settled: Not applicable Maturity date of the derivative (if any): Not applicable Expiry date of the derivative (if any): Not applicable The price's specified terms (if any): Not applicable Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: Not applicable For that derivative relevant interest,- Parties to the derivative: Not applicable If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: Not applicable Certification I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of director or officer: " " Date of signature: 17-Jun-20 End CA:00354820 For:AFT Type:SHINTR Time:2020-06-17 11:48:25